ArticleArchives of virology2026
Enhancing the immunogenicity of a recombinant PEDV subunit vaccine: the role of lipoprotein signal peptide.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spike (S) protein of Porcine Epidemic Diarrhea Virus (PEDV) is a major structural glycoprotein responsible for viral attachment and entry, making it a critical target for the development of subunit vaccines. Within the S1 domain, a well-characterized region spanning residues 499–799, commonly referred to as the core neutralizing epitope (COE) the equivalent of the CO-26 K domain, contains multiple predicted B-cell, T-cell, and virus-neutralizing epitopes, making it highly immunogenic. This study investigates whether the incorporation of a bacterial lipoprotein signal peptide into the COE domain can enhance its antigenicity and protective efficacy by inducing lipidation-mediated activation of Toll-like receptor 2 (TLR2). A truncated COE construct was engineered either with a signal peptide (SP-COE) or without one (COE), and evaluated through a combination of in-silico, in vitro, and in vivo analyses. In silico epitope prediction tools identified strong B-cell and T-cell epitope coverage within COE. Molecular docking revealed favorable interactions with immune receptors, and structural modeling demonstrated the construct’s stability. In vitro, HEK-Blue hTLR2 reporter cells revealed that SP-COE elicited significantly higher NF-κB activation compared to COE, confirming effective TLR2 engagement. In vivo, mice immunized with SP-COE displayed significantly elevated total IgG and virus-neutralizing antibody titers, enhanced cytokine responses (e.g., IFN-γ, IL-4), and a stronger CD4⁺ T-cell response relative to the COE group. These findings demonstrate that incorporating a lipoprotein signal peptide improves the immunogenicity and protective potential of the PEDV COE antigen, highlighting its utility as an intrinsic adjuvant in subunit vaccine design.
Indexed as
Identifiers
41848923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.